-

Shareholder Alert: Robbins LLP Reminds Investors that Evolus, Inc. (EOLS) is Being Sued for Misleading Shareholders

SAN DIEGO & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that Evolus, Inc. (NASDAQ: EOLS) is being sued for alleged violations of the Securities Exchange Act of 1934 between February 1, 2019 and July 6, 2020. Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. Evolus' sole product is Jeuveau™ competes with Botox®.

If you suffered a loss due to Evolus, Inc.'s misconduct, click here.

Evolus, Inc. (EOLS) Accused of Misappropriating Trade Secrets

According to the complaint, beginning in February 2019, Evolus began a campaign in which it promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by a Korean bioengineering company through years of clinical research. On July 6, 2020, the investing public learned the truth when the U.S. International Trade Commission ("ITC") issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, which claimed that Evolus stole trade secrets to develop Jeuveau. The ITC Judge determined that Evolus and its South Korean partner firm misappropriated the botulinum toxin and the manufacturing process that led to its development and manufacture. As a result, the ITC Judge recommended a ten-year long ban on Evolus' ability to import and sell Jeuveau in the United States. On this news, Evolus' stock dropped 37% in two days to close at $3.35 on July 8, 2020 and has yet to recover.

If you purchased Evolus, Inc. (EOLS) securities between February 1, 2019 and July 6, 2020, you have until December 15, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Evolus, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the United Homes Group, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired United Homes Group, Inc. (NASDAQ: UHG) securities between May 19, 2025 and February 22, 2026. United Homes is a residential home building company. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that United Homes Group, Inc. (UH...

Investor Notice: Robbins LLP Informs Investors of the Stellantis N.V. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stellantis N.V. (NYSE: STLA) securities between February 26, 2025 and February 5, 2026. Stellantis is a global automobile designer, engineer, manufacturer, and distributor.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Stell...

Investor Notice: Robbins LLP Informs Investors of Upstart Holdings, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Upstart Holdings, Inc. (NASDAQ: UPST) securities between May 14, 2025 and November 4, 2025. Upstart, together with its subsidiaries, operates a cloud-based artificial intelligence (“AI”) lending platform in the U.S.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins...
Back to Newsroom